Companion Diagnostic Coverage: What UnitedHealthcare Requires in 2026
Short answer: For UnitedHealthcare commercial and exchange plans, a companion diagnostic is covered when it carries FDA CDx status for the specific drug and indication, and the result will guide a targeted oncology therapy. Under UHC policy 2026T0653H, FDA approval alone is not a basis for coverage, so labs must document the matching drug, indication, and specimen scenario.
Why companion diagnostic coverage deserves its own workflow
Most molecular oncology denials are argued on medical necessity. Companion diagnostics (CDx) are different because the FDA has already tied the test to a drug. FDA defines a companion diagnostic as an in vitro diagnostic device or imaging tool that provides information essential for the safe and effective use of a corresponding therapeutic product. Payers have responded by writing dedicated policies that sit apart from their general molecular oncology rules. For labs and ordering clinicians, the question shifts from "is this test necessary?" to "does this exact test match this exact drug and indication?"
This article walks through one such policy, UnitedHealthcare Medical Policy 2026T0653H, "FDA Cleared or Approved Companion Diagnostic Testing," and what it implies for requisitions, documentation, and claims. It applies to UnitedHealthcare Commercial and Individual Exchange plans and became effective July 1, 2026. It does not describe Medicare; for Medicare NGS coverage, see our guide to NCD 90.2 and NGS coverage for cancer testing.
What the UHC policy covers
The policy states that it applies to tests granted approval as FDA cleared or approved companion diagnostics. It names specific tests as proven and medically necessary for specified indication and drug pairings: FoundationOne CDx, FoundationOne Liquid CDx, Guardant360 CDx, MI Cancer Seek, Oncomine Dx Express Test, Oncomine Dx Target Test, oncoReveal CDx, TruSight Oncology Comprehensive, and xT CDx.
It also leaves room for tests that are not on that named list. An unlisted FDA-cleared CDx is covered when two criteria are met. First, the results will inform use of a targeted oncology therapy in a person with the matching clinical indication. Second, the test appears in FDA's CDx table, or has an approval order in the FDA Premarket Approval Database that has not yet been added to the table, for that drug and indication. That second path matters because the FDA table can lag behind a new approval.
The five conditions a claim has to satisfy
Reading the coverage rationale as a checklist gives labs a practical way to audit orders before submission.
The first condition is CDx status. The test must be FDA cleared or approved as a companion diagnostic, either listed for the specific drug and indication or meeting the unlisted-test criteria above. The second is therapeutic intent: the result must inform management with a targeted oncology therapy for the matching clinical indication. The third governs repeat testing. Retesting on a new specimen is covered only when the criteria above are met and the disease has recurred, or the cancer progressed or did not respond to the most recent systemic therapy. The fourth governs concurrent testing. Tissue-based and liquid biopsy CDx testing together is covered for stage IV breast cancer and stage IV non-small cell lung cancer when the CDx criteria are met, and the policy defines concurrent testing as tissue and liquid biopsy ordered for the same clinical indication within a 30-day period. The fifth is documentation: medical records may be requested to confirm eligibility.
What the policy does not do
Three limits are easy to miss. The policy says that FDA approval alone is not a basis for coverage. It says that all other uses of the listed CDx tests are unproven and not medically necessary, citing insufficient evidence of efficacy. And it says the member's benefit plan document governs if it conflicts with the policy.
The policy also does not resolve coverage for molecular oncology tests that are not cleared or approved as CDx. It points those to separate UHC policies on molecular oncology testing for solid tumor cancer and for hematologic cancer. For labs running laboratory-developed tests, that is a different analysis, and our overview of the FDA LDT rule status gives regulatory context.
Coding: what the code list does and does not tell you
The policy lists these codes for reference: 0022U, 0037U, 0211U, 0239U, 0242U, 0473U, 0523U, 0543U, 0648U, and 81479. The 0648U code was added in the July 1, 2026 revision. UHC states the list is for reference only, may not be all inclusive, and that a listed code does not confirm coverage or guarantee payment.
The inclusion of 81479, the unlisted molecular pathology code, is a reminder that CDx claims can still land in unlisted-code territory. Labs that bill unlisted codes should review our guidance on CPT 81479 denials and make sure the test name, drug, and indication are visible in the claim narrative and supporting records.
A newly approved CDx: why the lag matters
New approvals keep arriving. On August 26, 2026, Roche announced FDA approval of two companion diagnostic tests, the PATHWAY HER2 (4B5) antibody test and the VENTANA HER2 Dual ISH DNA Probe Cocktail, to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma who may be eligible for ZIIHERA (zanidatamab-hrii). Roche's release states that no tests had previously been approved to determine HER2 status in esophageal cancer; that is the company's claim.
The practical lesson for billing teams is timing. A payer policy effective July 1 cannot name a test approved on August 26. In the UHC policy, the unlisted-test pathway, which allows a Premarket Approval Database order that is not yet in the FDA table, is the mechanism designed for that gap. FDA's CDx list page was last modified on November 3, 2026, so the table itself is a moving target. We have not verified how UHC treats these two HER2 tests, and labs should confirm against the current policy before relying on them.
Operational checklist for labs and ordering teams
Start by capturing the drug and indication on the requisition, because the policy ties coverage to both. Build a lookup against the FDA CDx table and the therapeutic product's labeling, which FDA notes also governs use of the companion diagnostic. Flag any order for retesting and require a recurrence, progression, or non-response note. Flag concurrent tissue and liquid orders and confirm the indication is stage IV breast or stage IV NSCLC and that both fall within the 30-day window. Finally, route non-CDx orders to the appropriate molecular oncology policy rather than assuming CDx rules apply. These controls also reduce exposure to the denial patterns described in our guide to genetic testing denials and the front-end steps in prior authorization for genetic testing. See also UnitedHealthcare genetic testing prior authorization in 2026.
Platforms like ScreenMyGene help teams standardize this kind of order-to-claim logic so that requisition data matches payer criteria before submission.
Frequently asked questions
Does FDA approval of a CDx guarantee payment?
No. UHC's policy states that FDA approval alone is not a basis for coverage. The test must match the listed or FDA-recognized drug and indication, the result must inform a targeted therapy, and the member's plan document governs if it conflicts with the policy.
Are tissue and liquid biopsy CDx tests covered together?
Under this policy, concurrent tissue and liquid biopsy CDx testing is covered for stage IV breast cancer and stage IV non-small cell lung cancer when CDx criteria are met. Concurrent means ordered for the same clinical indication within a 30-day period.
Can a CDx be retested?
Retesting on a new specimen is covered when the CDx criteria are met and the disease has recurred, or the cancer progressed or did not respond to the most recent systemic therapy. Routine repeat testing without those events is not described as covered.
What if a test is not on UHC's named list?
An unlisted FDA-cleared CDx can be covered if results inform a targeted oncology therapy for the matching indication and the test appears in FDA's CDx table, or has a Premarket Approval Database order not yet in the table, for that drug and indication.
Does this policy apply to Medicare?
No. Policy 2026T0653H applies to UnitedHealthcare Commercial and Individual Exchange plans. Medicare coverage for cancer NGS is addressed separately, including under national coverage determination 90.2, and Medicare contractors apply their own documentation and billing rules, so labs should not assume the UHC criteria carry over.
This article is for educational purposes only and is not legal, coding, reimbursement, or medical advice. Payer policies change, and plan documents control. Verify requirements with the payer and qualified compliance counsel before acting.
Sources: UnitedHealthcare Medical Policy 2026T0653H, FDA Cleared or Approved Companion Diagnostic Testing (effective July 1, 2026); FDA, List of FDA-Authorized Companion Diagnostic Devices; Roche Diagnostics, HER2 companion diagnostic approval for ZIIHERA (August 26, 2026).